Big pharma joins hunt for coronavirus vaccine as outbreak escalatesBig pharma has joined the hunt for a vaccine for the deadly coronavirus outbreak that is beginning to Share XBig pharma joins hunt for coronavirus vaccine as outbreak escalateshttps://pharmaphorum.com/news/big-pharma-joins-hunt-for-coronavirus-vaccine-as-outbreak-escalates/
Investigator sponsored trials begin making waves in R&DIncreasing numbers of pharma companies are forgoing CROs to partner with academic centres on investigator sponsored trials (ISTs). Share XInvestigator sponsored trials begin making waves in R&Dhttps://pharmaphorum.com/r-d/views-analysis-r-d/investigator-sponsored-trials-begin-to-make-waves-in-rd/
Roche edges closer to SMA market as risdiplam hits target in trial in babiesRoche is to begin discussions with regulators about new data from risdiplam, its developmental oral treatment for the Share XRoche edges closer to SMA market as risdiplam hits target in trial in babieshttps://pharmaphorum.com/news/roche-sma-risdiplam-babies/
AstraZeneca commits to being carbon negative by 2030AstraZeneca has announced its ambition to have zero carbon emissions from its global operations by 2025 and to Share XAstraZeneca commits to being carbon negative by 2030https://pharmaphorum.com/news/astrazeneca-commits-to-being-carbon-negative-by-2030/
Making real world evidence fit for purposeAlthough real world evidence (RWE) is a hot topic in pharma right now, many still question whether it Share XMaking real world evidence fit for purposehttps://pharmaphorum.com/views-analysis-market-access/making-real-world-evidence-fit-for-purpose/
UK biotech PhoreMost to work with Otsuka on gene therapy projectsBuilding on an R&D tie-up with an Indian stem cell institution last year, UK biotech PhoreMost has begun Share XUK biotech PhoreMost to work with Otsuka on gene therapy projectshttps://pharmaphorum.com/news/uk-biotech-phoremost-to-work-with-otsuka-on-gene-therapy-projects/
AI-powered study backs anticoagulants for heart failure patients without AFA new study has found that blood thinning drugs improve outcomes for all heart failure patients, regardless of Share XAI-powered study backs anticoagulants for heart failure patients without AFhttps://pharmaphorum.com/news/ai-powered-study-backs-anticoagulants-for-heart-failure-patients-without-af/
WHO criticises lack of big pharma antibiotic R&DBig pharma still continues to look upon antibiotic resistance as somebody else’s problem, the World Health Organization has Share XWHO criticises lack of big pharma antibiotic R&Dhttps://pharmaphorum.com/news/who-bemoans-lack-of-big-pharma-antibiotic-rd/
Despite benefits, blockchain adoption is slow in life sciences, says reportWidespread adoption of blockchain could add $3 billion-worth of value to life sciences companies by 2025, but adoption Share XDespite benefits, blockchain adoption is slow in life sciences, says reporthttps://pharmaphorum.com/news/despite-benefits-blockchain-adoption-is-slow-in-life-sciences-says-report/
